Replimune Group, Inc. (REPL) Dividend History

Company News

• Melanoma Market Anticipates a Dynamic Shift During the Forecast Period (2025–2034) Owing to the Strong Pipeline Activity | DelveInsight

  The melanoma market is expected to surge between 2025-2034 due to increasing incidence, emerging therapies, heightened UV exposure, and diagnostic advancements. Several new therapies are in development, with potential to transform treatment options for melanoma patients.

  GlobeNewswire Inc.

  Featured Companies: BMY IDYA
• Replimune (REPL) Gains on Positive Data From Melanoma Study

  Replimune's (REPL) lead pipeline candidate RP1, in combination with Opdivo, leads to an overall response rate of 33.6% in patients with anti-PD1 failed melanoma. Shares gain.

  Zacks Investment Research

  Featured Companies: ALXO BMY KRYS
• Barclays Maintains Overweight Rating for Replimune Group: Here's What You Need To Know

  Barclays has decided to maintain its Overweight rating of Replimune Group (NASDAQ:REPL) and lower its price target from $50.00 to $13.00. Shares of Replimune Group are trading up 0.3% over the last 24 hours, at $6.77 per share. A move to $13.00 would account for a 92.02% increase from the current share price. About Replimune Group Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or ...Full story available on Benzinga.com

  Benzinga
• Billionaires Are Scooping Up These 3 Beaten-Down Biotech Stocks

  This billionaire-guided hedge fund went bargain-shopping in the second quarter.

  The Motley Fool

  Featured Companies: BMY CERS REGN